Mendus AB

Equities

IMMU

SE0005003654

Biotechnology & Medical Research

Delayed Nasdaq Stockholm Other stock markets 07:27:59 2024-04-29 am EDT			5-day change	1st Jan Change
0.46 ^SEK	-3.06%		-6.12%	-12.05%

Apr. 16	Mendus AB Announces Board Changes	CI
Mar. 27	Mendus AB Announces Ethics Committee Approval for the AMLM22-CADENCE Trial with Lead Product Vididencel in AML	CI

Mendus to participate in several investor and industry conferences in January

January 08, 2024 at 02:01 am EST

Press release

Stockholm, Sweden, January 8, 2024

Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, today announced that it will participate in the following upcoming investor and industry conferences:

42^nd Annual J.P. Morgan Healthcare Conference

San Francisco, USA, January 8-11, 2024

Mendus management team will be in San Francisco for business and investor meetings during the J.P, Morgan conference

https://www.jpmorgan.com/about-us/events-conferences/health-care-conference

13th Annual LifeSci Partners Corporate Access Event

San Francisco, USA, January 8-10, 2024

Mendus will take part in the LifeSci Corporate Access investor event

https://lifescievents.com/event/cae2024/

Redeye Theme: Fight Cancer

Stockholm, Sweden, January 24, 2024

Mendus CEO Erik Manting will present the company and take part in a discussion panel

https://www.redeye.se/events/966280/redeye-theme-fight-cancer-2

FOR MORE INFORMATION, PLEASE CONTACT:

Erik Manting, CEO

E-mail: ir@mendus.com

ABOUT MENDUS AB (PUBL)

Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. http://www.mendus.com/

Attachment

240108 Mendus_Conferences_ENG_final

Latest news about Mendus AB

Mendus AB Announces Board Changes	Apr. 16	CI
Mendus AB Announces Ethics Committee Approval for the AMLM22-CADENCE Trial with Lead Product Vididencel in AML	Mar. 27	CI
Transcript : Mendus AB - Special Call	Mar. 12
Transcript : Mendus AB, 2023 Earnings Call, Feb 14, 2024	Feb. 14
Mendus AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 13	CI
Certain Ordinary Shares of Mendus AB are subject to a Lock-Up Agreement Ending on 27-JAN-2024.	Jan. 26	CI
Mendus AB Announces Clinical Pipeline Update	Dec. 22	CI
Transcript : Mendus AB - Special Call	Dec. 14
Mendus AB Appoints Ted Fjällman as Board Member	Dec. 13	CI
Mendus AB Announces Positive Survival Data from Phase 2 Advance II Trial Evaluating Vididencel as Maintenance Therapy for AML at ASH 2023	Dec. 11	CI
Mendus AB and Australasian Leukaemia & Lymphoma Group to Expand Clinical Testing of Vididencel as Maintenance Treatment for AML	Dec. 06	CI
Mendus Announces appointment of Nomination Committee for the 2024 Annual General Meeting	Nov. 17	CI
Transcript : Mendus AB, Nine Months 2023 Earnings Call, Nov 09, 2023	Nov. 09
Mendus AB Presents Updated Alison Clinical Trial Data for Vididencel in Ovarian Cancer At SITC 2023	Nov. 06	CI
Mendus Announces Phase 1 vididencel Clinical Trial Results in AML and High-Risk MDS Patients Published in Peer-Reviewed Medical Journal	Nov. 03	CI
Mendus AB Announces Multiple Abstracts to Be Presented At Ash 2023 Including Oral Presentation on Advance Ii Survival Data	Nov. 02	CI
Mendus AB to Present Novel Data Supporting the Broad Potential of its Proprietary Cancer Vaccine Platform at CICON23	23-09-21	CI
Mendus Obtains US FDA's Fast Track Tag for Blood Cancer Therapy	23-09-08	MT
Mendus AB Receives U.S. FDA Fast Track Designation forididencel in Acute Myeloid Leukemia	23-09-08	CI
Mendus AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-29	CI
Mendus AB Announces the Publication of Novel Preclinical Data on its Intratumoral Priming Strategy in the Peer-Reviewed Medical Journal 'Frontiers in Immunology	23-08-16	CI
Mendus AB announced that it has received funding from Flerie Invest AB	23-07-30	CI
Transcript : Mendus AB - Special Call	23-06-27
Mendus AB Appoints Lewis Lanier to Scientific Advisory Board	23-06-20	CI
Sweden’s Mendus Receives European Medicines Agency Certification for Cancer Vaccine	23-06-19	MT

Chart Mendus AB

Duration

Period

More charts

Company Profile

Mendus AB (publ), formerly Immunicum AB, is a Sweden-based company that is engaged in the biopharmaceutical sector. The Company develops immunotherapy for therapeutic treatment of cancer and infectious diseases. The Company develops off-the-shelf, cell-based products that are immunogenic based on underlying allogeneic dendritic cell biology and which have the potential to activate the patientâs own immune system against cancer. The Companyâs programs ilixadencel and DCP-001 are derived from healthy donor material and from Company's DCOne cell line, respectively. The Company develops ilixadencel to address the tumor burden of established tumors via intratumoral immune priming and DCP-001 as a cancer relapse vaccine, aimed at the reduction of tumor recurrence following initial treatment. Mendus has offices in Sweden and the Netherlands.

Sector

Biotechnology & Medical Research

Calendar

2024-05-16 - Annual General Meeting

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MENDUS AB	-12.05%	43.59M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+48.09%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research

Mendus AB

Equities

IMMU

SE0005003654

Biotechnology & Medical Research

Mendus to participate in several investor and industry conferences in January

Latest news about Mendus AB

Chart Mendus AB

Company Profile

Income Statement Evolution

EPS Revisions

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research